Why Attend
With deals in the protein degradation market reaching nearly $2 billion and unique degradation ideas coming into play such as LYTACs and ENDTACs, eyes are focused on how much further protein degradation-based therapeutics will continue to grow
within the pharmaceutical industry.
Following huge success in May 2019, the 2nd European Protein Degradation Congress, returns to Switzerland 12th - 13th May 2020, where you can hear the most up to date and relevant information for the broad range of topics in the field of targeted
protein degradation.
New areas will cover novel methods in harnessing E3 ligases and the latest discoveries from PROTACs and molecular glues with preclinical and clinical data being shown.
Leading industry players from biotechs and big pharma will come together to exchange thoughts on how to best overcome obstacles to achieving reliable in vitro and in vivo data. Academic experts will be present their latest research to help build a deeper understanding of the mechanisms involved in the Ubiquitin pathway, providing a clearer picture on what makes a good, or not good, target for degradation.
Poster Submission 2020
Looking to showcase your recent work to the protein degradation community?
Our dedicated poster session is the perfect way to get your research noticed. In order to present a poster at the forum you need to be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration). At the congress, your presentation will be displayed in a dedicated poster area. The poster presentation session will take place at the afternoon networking break on day one.
Poster abstract submission deadline is on 10 April 2020. Posters should be sized A0 (841mm x 1189mm) in portrait orientation.
Abstracts received after this time may not be accepted so please submit your abstract as soon as possible!
If you have any questions please contact [email protected]
Previous Attendees Include
highlights from 2019
Talk to our speakers about...
1. How to exploit protein homeostasis to identify new proteins for degradation
2. How to find new E3 ligase recruiters
3. What does the next generation of targeted protein degradation products look like?
4. How can chemo-proteomics be used to make the ‘undruggable’ druggable?
5. Structural-based design of PROTAC through crystallography techniques
6. Furthering our understanding of the ubiquitin space.
7. New synthetic molecular glue approaches from auxin scaffolds
8. How mechanistic understanding of the DUBs space is applicable to targeted protein degradation
9. How well do PROTACs work in clinical application – insights into the first human trial
10. Key medicinal chemical considerations for moving from a PROTAC/molecular glue probe to drug
Audience Breakdown
What attendees say
Speakers
Nico Thoma
Phil Chamberlain
Alfred Goldberg
Claudio Joazeiro
Broadly we are interested in the E3 ubiquitin ligases –their biological functions, mechanism of action, and roles in disease. For the past few years, we have focused on the problem of how cells know when its proteins are aberrant or damaged, and then decide on ways to either correct or eliminate them. Protein quality control is critical to ensure proteome integrity and cellular fitness; further underscoring its relevance, defective protein quality control is a hallmark of neurodegenerative diseases.
In eukaryotic organisms, key factors conferring specificity to protein quality control are molecular chaperones and E3 ligases. We have recently discovered a novel protein quality control mechanism mediated by an E3 ligase, Listerin/Ltn1, and which takes place on ribosomes. We now know that Listerin functions as a subunit of the Ribosome-Associated Quality Control (RQC) complex, which is conserved from yeast to humans. Of relevance, Listerin mutation causes motor neuron degeneration in mice.
We employ diverse model systems and approaches to elucidate how RQC-mediated quality control occurs at the cellular and molecular levels, including biochemistry, yeast genetics, cell biology, mouse models of neurodegeneration, and structural biology. We also analyze patients’ genomes to identify mutations that affect protein quality control; these studies are leading to insights onto the molecular basis of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases, and to potential therapeutic targets.
In addition to the projects on Listerin, we have been working to elucidate the functions and mechanisms of the mitochondria-anchored E3 ligase, MULAN/MUL1, and to develop small molecule inhibitors of E3 ligases that can be used as oncology therapeutics.
Gwenn Hansen
Gwenn is Vice President of Drug Discovery Technologies at Nurix Therapeutics, a company focused on discovering and developing next-generation therapies that target protein homeostasis through modulation of the ubiquitin proteasome system. Since joining Nurix in January of 2016, Gwenn has focused on establishing the company’s DNA encoded library technology platform for small molecule discovery, and now leads teams of scientists in both early discovery as well as medicinal chemistry. Prior to joining Nurix, Gwenn spent one year as an Associate Professor in the Center for Drug Discovery at Baylor College of Medicine and over 13 years in a variety of discovery-focused roles at Lexicon Pharmaceuticals, both located in Houston, Texas. Gwenn received her PhD in Biomedical Sciences from Oak Ridge National Laboratory in 1998 and completed postdoctoral training at MD Anderson Cancer Center.
Manfred Koegl
I am a director in Oncology Research at Boehringer Ingelheim in Vienna, working on the discovery and implementation of new therapeutic concepts in cancer. The main focus of my team are novel approaches for cancer cell targeting by small molecule drugs.
Andreas Martin
Marjeta Urh
My role as Director in R&D at Promega is to develop novel technologies and research tools for analysis of nucleic acids and protein function. The breadth of technologies developed in my group span mass spectrometry, novel immunoassays, analysis of protein-protein and protein-small molecule interactions and targeted protein degradation. In addition, my group is involved in developing applications of Promega core technologies such as HaloTag, NanoBRET, NanoBiT and HiBiT technologies.
Markus Quessier
Radoslaw Nowak
Laura Itzhaki
Xavier Lucas
Cristina Mayor-Ruiz
Markus Muellner
Olivier Coux
Michal Walczak
Sharon Townson
Boxun Lu
Huib Ovaa
Helena Danielson
Frank Mercurio
Gopal Sapkota
Zhengnian Li
Andy Pike
Simon Bailey
Matthias Wittwer
Willem Nissink
Expertise Partners
Promega
Website: https://www.promega.com
Promega Corporation is a world leader in providing innovative solutions to the life sciences. We develop bioluminescent technologies that deliver more biologically relevant data for small and large molecule drug discovery. We are the commercial leader in offering sensitive, real-time assays for PROTACs and Protein Degradation. Is my target protein degraded? Is it recruited to the proteasome? Is my PROTAC cell permeable? Speak with a Promega representative to learn how to answer these questions. For more information www.promega.com.
Pelago Bioscience AB
Website: https://www.pelagobio.com/
Pelago Bioscience AB established in 2013 provides and develops the patented Cellular Thermal Shift Assay (CETSA®) for use in determination and quantification of drug–target interactions, to accelerate drug discovery and diagnostics development. CETSA® provides a quantitative measure of target engagement and the biophysical readout of affinity, and adds real value to existing efficacy assays. We deliver complete target engagement hit confirmation data sets, develop and validate assays for use in screening cascades, and profile candidate drugs based on the CETSA® method, tailored to the project need. For larger volumes and portfolios we offer tech transfer and sublicensing of the CETSA® method.
Event Partners
Fluidic Analytics
Website: https://www.fluidic.com/
Fluidic Analytics- Understand the machinery of life
With the right tool, protein researchers can change the world around us.
Our award-winning technologies open doors for scientists to understand proteins and their behavior better than ever before. By characterizing proteins and their interactions, scientists can make better decisions about how we diagnose diseases, develop treatments and maintain our personal well-being. Our revolutionary technologies give researchers a fundamentally new way to analyze proteins without compromise, because we truly believe the right tools in the right hands will change the world.
Proteome Sciences
Website: https://www.proteomics.com/
Proteome Sciences is a Contract Research Organisation (CRO) specialising in the analysis of proteins detected by Mass Spectrometry. We offer various Discovery and Targeted Services to characterise proteins and their associated post translational modifications.
By using LC-MS2, LC-MS3, SysQuant® and TMTcalibratorTM methodologies on samples that originate from tissue to biological fluids, we can detect over 8,000 proteins per sample. With our proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated in either disease progression or drug treatment.
Using our unique TMTpro isobaric mass tags, we can run up to 15 samples per single experiment thereby allowing relative protein quantification between samples. By using a reference channel, multiple experiments can be performed sequentially, thereby allowing 30 to 100+ samples to be characterized in one project. Sensitivity is equivalent to conventional ELISA in many cases.
In the clinical area, we offer single or multiplexed protein measurements on customer selected proteins either with or without a PTM. Proteins selected can be either known previously, or more often detected above via our Discovery Services. We can measure up to 100 multiplex proteins per sample in a GCLP accredited Targeted Mass Spectrometric assay using clinically relevant samples such as plasma and CSF. Again, sensitivity is equivalent to conventional ELISA in many cases.
BioTheryX
Website: https://www.biotheryx.com/
BioTheryX, Inc., founded by the drug development team behind the remarkable IMiDs® franchise of compounds, is applying its extensive and proven clinical and commercial success to deliver efficacious therapies to patients with unmet medical needs focusing on orally available small molecules for the treatment of cancers and inflammatory diseases. Our lead molecule is currently in Phase I clinical trial for Acute Myeloid Leukemia and high-risk MDS and our lead protein degradation “molecular glue” molecule (Protein Homeostatic Modulator or PHM®) will be in the clinic in 2021 for hematological malignancies.
Aurelia Biosciences
Website: https://www.aureliabio.com/
Please visit our website for more information.
The Agenda
Please complete the from to receive the full agenda for 2020, including information about the key topics being covered, speakers, and why you should attend.
What you can expect from the 2020 congress:
- 200+ participants from leading industry players within big pharma and biotech along with expert academics in the ubiquitin space.
- An open forum to share the latest in vivo and in vitro data and insights and foster collaboration.
- 18+ thought leaders on the speaking agenda and ready to answer your big questions on overcoming translational hurdles.
- 2 days of progressing translation of protein degradation probes into safe, effective therapeutics.
Download Agenda
Become a Sponsor
Kisaco Research provides the much-needed platform on which industry executives can network, connect and learn from each other as well as meet potential industry partners.
Far from the typical ‘meet-and-greet’ exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.
With our extensive marketing experience and strategy, your partnership with Kisaco Research will grant you a sponsorship package that is an extension and enhancement of your current marketing and branding efforts. We value your ROI and will work with you directly on your specific goals and targets – that’s why we take special care in finding the most relevant end-users to attend, so that your financial and resource investment is smartly allocated.
Find out more by calling us at +44 (0)20 3696 2920 or email us at [email protected].
Conference Packages
Sending Your Team? Group Discounts Available!
Applicable for Primary Market, Service Provider and Industry Rates Only. Not available for Academic or ‘Start-Up’ rates
Book a Team of 3+ - Save an Additional 10% Off
Book a Team of 5+ - Save an Additional 15% Off
If you would like to register a team of 3 or more, please email [email protected] for your discount coupon code before registering. PLEASE NOTE: Discounts cannot be combined with Early Bird Pricing or any other discount or offer. If you have any questions about your registration, please call us on +44 (0)20 3696 2920
Ticket prices increase in
About Kisaco Research
Kisaco Research produces, designs and hosts B2B industry conferences, exhibitions and communities – focused on a specialized selection of topic areas.
Meet industry peers that will help build a career-changing network for life.
Learn from the mistakes of your peers as much as their successes—ambitious industry stalwarts who are happy to share not just what has made them successful so far but also their plans for future proofing their companies.
Note down the inspired insight that will form the foundation for future strategies and roadmaps, both at our events and through our online communities.
Invest both in your company growth and your own personal development by signing up to one of our events and get started.